Laird Norton Wetherby Wealth Management LLC Invests $472,000 in Inhibrx, Inc. (NASDAQ:INBX)

Laird Norton Wetherby Wealth Management LLC purchased a new position in Inhibrx, Inc. (NASDAQ:INBX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 30,656 shares of the company’s stock, valued at approximately $472,000. Laird Norton Wetherby Wealth Management LLC owned about 0.21% of Inhibrx as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the business. PNC Financial Services Group Inc. bought a new position in shares of Inhibrx in the 4th quarter worth about $28,000. Natixis bought a new stake in Inhibrx in the 4th quarter valued at about $31,000. JPMorgan Chase & Co. lifted its position in Inhibrx by 47.8% in the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company’s stock valued at $117,000 after purchasing an additional 2,457 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx in the 4th quarter valued at about $47,000. Finally, New York State Common Retirement Fund bought a new stake in Inhibrx in the 4th quarter valued at about $53,000. 82.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research report on Thursday.

Inhibrx Trading Up 10.9%

Shares of NASDAQ:INBX opened at $12.02 on Friday. The company’s 50-day moving average price is $12.66 and its 200 day moving average price is $13.69. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $34.73.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($2.55) by ($0.25). As a group, research analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.